New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 16, 2014
07:02 EDTISISIsis Pharmaceuticals reports final Phase 2 data on ISIS-GCGR Rx
Isis Pharmaceuticals announced the final results from its Phase 2 study of ISIS-GCGRRx in patients with type 2 diabetes uncontrolled on stable metformin therapy. In this study, patients in the per protocol population treated with ISIS-GCGRRx in addition to metformin achieved absolute mean reduction in hemoglobin A1c of up to 2.25 percentage points from baseline after only 13 weeks of treatment. Patients receiving placebo had an 0.25 percentage point reduction in HbA1c. In this study, more than half of the PP patients achieved an HbA1c level of less than or equal to 7.0 percent. PP patients treated with ISIS-GCGRRx in this study also achieved a mean reduction of up to 74.9 Ámol/L in fructosamine. In addition, in these patients a mean increase in total GLP-1 of up to 19.97 pmol/L was observed.
News For ISIS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 27, 2015
09:43 EDTISISIsis Pharmaceuticals sees reporting data on eight or more drugs in FY15
Sees initiating up to 13 studies, broadening pipeline with up to five new drugs in partnered, unpartnered programs.
09:38 EDTISISIsis Pharmaceuticals sees FY15 pro forma NOL in mid-$50M range
Sees ending FY15 with more than $630M in cash, representing net cash outflows of only $100M to move forward its pipeline.
09:34 EDTISISIsis Pharmaceuticals reports Q4 EPS 25c, consensus 2c
Subscribe for More Information
February 26, 2015
15:30 EDTISISNotable companies reporting before tomorrow's open
Subscribe for More Information
February 24, 2015
10:48 EDTISISIsis says ISIS-PKKRx reduced prekallikrein levels in Phase 1 study
Isis Pharmaceuticals announced results from a Phase 1 study with ISIS-PKKRx. In this study, healthy volunteers treated with ISIS-PKKRx achieved dose-dependent reductions of up to 95% in prekallikrein, or PKK, Isis said. ISIS-PKKRx is a RNA-targeted antisense drug designed to inhibit the production of PKK for the prophylactic treatment of hereditary angioedema. ISIS-PKKRx was evaluated in single and multiple doses ranging from 50 mg per week up to 400 mg per week for the single dose and 100 mg up to 400 mg for the multiple doses. After three weeks of dosing, subjects in the 100, 200, 300 and 400 mg multiple-dose cohorts displayed a mean reduction of PKK of 33, 69, 87 and 92%, respectively, from baseline. In this study, ISIS-PKKRx was generally well tolerated.
February 23, 2015
07:22 EDTISISSunTrust to hold a conference
2015 Biotechnology and Pharmaceutical 1:1 Orphan Drug Day is being held in New York on February 23.
February 20, 2015
15:20 EDTISISIsis Pharmaceuticals management to meet with JPMorgan
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use